GGrantIndex
← Search

QUALITY OF LIFE

$78,870U10FY2002CANIH

Mayo Clinic Coll Of Medicine, Rochester, Rochester MN

Investigators

Linked publications, trials & patents

Paper 39055377Paper 37539667Paper 36050448Paper 35859079Paper 34804634Paper 33154022Paper 32923882Paper 32504284Paper 31802506Paper 31213748Paper 30775161Paper 29848457Paper 29649081Paper 29530935Paper 29313954Paper 29164377Paper 29138761Paper 29044496Paper 28939223Paper 28921241Paper 28917648Paper 28786105Paper 28700816Paper 28691116Paper 28691057Paper 28687377Paper 28649983Paper 28646344Paper 28620884Paper 28533226Paper 28493308Paper 28402581Paper 28384065Paper 28375706Paper 28323331Paper 28280603Paper 28262692Paper 28239505Paper 28089762Paper 28006055Paper 27943153Paper 27881709Paper 27590208Paper 27534963Paper 27478689Paper 27468630Paper 27458945Paper 27374464Paper 27365012Paper 27302508Paper 27197192Paper 27098150Paper 27075674Paper 27060850Trial NCT01648348Trial NCT01369849Trial NCT01086605Trial NCT00869401Trial NCT00826540Trial NCT00738881Trial NCT00731731Trial NCT00699491Trial NCT00684983Trial NCT00641706Trial NCT00528645Trial NCT00459862Trial NCT00398112Trial NCT00369655Trial NCT00329719Trial NCT00321724Trial NCT00316849Trial NCT00255762Trial NCT00238394Trial NCT00238303Trial NCT00110084Trial NCT00109967Trial NCT00098540Trial NCT00096434Trial NCT00096070Trial NCT00093756Trial NCT00079274Trial NCT00079235Trial NCT00052949Trial NCT00052689Trial NCT00049127Trial NCT00039494Trial NCT00033267Trial NCT00027612Trial NCT00026234Trial NCT00026182Trial NCT00016328Trial NCT00015990Trial NCT00015821Trial NCT00014170Trial NCT00006226Trial NCT00005970Trial NCT00005036Trial NCT00003869Trial NCT00003140Patent 8507518

Abstract

Our primary goal is to assess only relevant endpoints that have tangible outcomes for cancer patients and clinical practice. Over the previous grant period, QOL research has been organized into a programmatic approach following three themes: 1) assessing QOL endpoints efficiently within treatment trials; 2) designing trials targeted specifically to QOL endpoints; and 3) developing new QOL methodology. Cancer treatment delivery can be improved through direct intervention to impact QOL endpoints, improved QOL assessment methods, or interventions to ameliorate concomitant side effects. A barrier to the development of these research efforts has been the lack of dedicated resources. Preliminary Work: A guiding principle of our preliminary work can be summarized as "less is more". We demonstrated that a single item global QOL instrument can display greater sensitivity to change than a multi- tem tool aimed at the same construct. We use minimally sufficient sets of individual QOL items and a prior clinically significant effect sizes. Preliminary Work: A guiding principle of our preliminary work can be summarized as "less is more." We demonstrated that a single item global QOL instrument can display greater sensitivity to change than a multi- item tool aimed at the same construct. We use minimally sufficient sets of individual QOL items and a priori clinically significant effect sizes. Clinical trials work includes pilot studies that target QOL endpoints (such social support) which impact directly on the ability to receive and tolerate cancer treatments and special populations (e.g., the elderly). Methodological advances include new tools, approaches, and analytical methods for combining QOL data with the traditional treatment endpoints of survival and response. This work also impacts the design of and accrual to cancer treatment trials. Future Directions: We have identified major issues for QOL research which will be addressed across all disease committees. We will define clinical significance for QOL endpoints by hosting an international meeting with the purpose of drafting a consensus document. Other research targets the use of individual questions as clinical intervention triggers and the use of proxy respondents to address the issue of missing data. We will construct an assessment package to identify frail elderly cancer patients so that modified treatments can be developed and linkage programs established within the community oncology practices to address deficits in individual patient social support. We will also explore the use of complementary therapies for pain management, including music and massage. Summary: The unique community practice-based structure of NCCTG has fostered the development of efficient, programmatic, and pragmatic, and pragmatic QOL research. We are at a critical juncture whereupon the present activity can be grown into a fully funded and functional program.

View original record on NIH RePORTER →